Insurance Status and Tumor Necrosis Factor Inhibitor Initiation Among Children With Juvenile Idiopathic Arthritis in the CARRA Registry

CARRA Registry Investigators

Research output: Contribution to journalArticlepeer-review

Abstract

Objective. Prompt escalation to tumor necrosis factor inhibitors (TNFis) is recommended for children with juvenile idiopathic arthritis (JIA) and ongoing disease activity despite treatment with conventional disease-modifying antirheumatic drugs (cDMARDs). It is unknown whether these recommendations are equitably followed for children with different insurance types. We assessed the association of insurance coverage on the odds and timing of TNFi use. Methods. We conducted a retrospective study of children with newly diagnosed JIA in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry. We compared the odds of starting a TNFi in the first year and time from cDMARD to TNFi initiation between those with public and private insurance. Results. We identified 1086 children with new JIA diagnoses. Publicly insured children had significantly higher active joint counts and parent/patient global assessment scores at the enrollment visit. They were also more likely to have polyarticular arthritis compared to those with private insurance. Odds of any TNFi use in the first year did not differ between publicly and privately insured children. Publicly insured children were escalated from cDMARD to TNFi more quickly than privately insured children. Conclusion. Children who were publicly insured had more severe disease and polyarticular involvement at registry enrollment compared to those who were privately insured. Whereas overall TNFi use did not differ between children with different insurance types, publicly insured children were escalated more quickly, consistent with their increased disease severity. Further research is needed to determine why insurance coverage type is associated with disease severity, including how other socioeconomic factors affect presentation to care.

Original languageEnglish
Pages (from-to)1047-1057
Number of pages11
JournalJournal of Rheumatology
Volume50
Issue number8
DOIs
StatePublished - 2023

Funding

FundersFunder number
Samara Jan Turkel Center
National Institutes of Health
National Institute of Allergy and Infectious DiseasesT32AI007512
National Institute of Allergy and Infectious Diseases
Arthritis Foundation
Washington Research Foundation
Lupus Foundation of America
Bristol-Myers Squibb
Rheumatology Research Foundation
Childhood Arthritis and Rheumatology Research Alliance

    Keywords

    • Medicaid
    • antirheumatic agents
    • health insurance
    • juvenile idiopathic arthritis
    • social determinants of health
    • tumor necrosis factor inhibitors

    Fingerprint

    Dive into the research topics of 'Insurance Status and Tumor Necrosis Factor Inhibitor Initiation Among Children With Juvenile Idiopathic Arthritis in the CARRA Registry'. Together they form a unique fingerprint.

    Cite this